Teon Therapeutics (US)

https://www.teonthera.com

LinkedIn: https://www.linkedin.com/company/teon-therapeutics-inc

Teon Therapeutics is a privately-held, clinical-stage biopharmaceutical companydedicated to improving the lives of cancer patients by developing a focused portfolio of small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that will enter Phase1b trials in 2021. The experienced leadership team are experts in adenosine and GPCR therapeutics and were primary inventors of Lexiscan®, the only FDA-approved selective adenosine therapeutic, which contributed to the acquisition of CV Therapeutics by Gilead. Northern LightVenture Capital led the company’s $7M Seed round. *

	Start	2021-02-22 existent
	Industry	TT-702 (Teon Therapeutics)
	Industry 2	immunotherapy
	Person	Yao, Lina (Teon Therapeutics 202102 CEO + Founder)

	Region	Redwood City, CA
	Country	United States (USA)
	Street	555 Twin Dolphin Drive Suite 120
	City	94065 Redwood City, CA
	Tel	+1-650-486-1902
		Address record changed: 2021-03-15

Basic data	Employees	n. a.

		* Document for »About Section«: Teon Therapeutics. (2/22/21). "Press Release: Teon Therapeutics Completes $30 Million Series A Financing". San Francisco, CA.

		Record changed: 2023-07-10

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Teon Therapeutics (US)

[1] Teon Therapeutics. (2/22/21). "Press Release: Teon Therapeutics Completes $30 Million Series A Financing". San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]